文献速递抗栓抗凝管理特殊人群用药

连续流左心室辅助装置后华法林治疗范围时间预测因素

Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device.
PubMed 文献 · Pharmacotherapy · 2019-10-07

本研究为单中心回顾性分析,纳入121例植入连续流左心室辅助装置(CF-LVAD)的患者,记录出院后门诊至装置使用12个月的国际标准化比值。多变量线性回归显示,年龄每增加1岁与TTR增加0.4%相关(p=0.008),距诊所每远1英里与TTR增加0.08%相关(p=0.03);女性与TTR降低10.1%相关(p=0.04),2型糖尿病与TTR降低11.5%相关(p=0.006),既往华法林使用与TTR降低8.3%相关(p=0.03)。

要点

  • 年龄增长和距诊所距离增加是CF-LVAD患者华法林高TTR的独立预测因素。
  • 女性、2型糖尿病和既往华法林使用是低TTR的独立预测因素。
  • 对具备低TTR预测因素的患者应加强抗凝管理。

核心结论

  • 在接收华法林的CF-LVAD患者中,年龄增长和距诊所距离增加是较高TTR的独立预测因素,女性、2型糖尿病和既往华法林使用是较低TTR的独立预测因素。

研究设计与样本

  • 回顾性单中心分析,纳入121例植入CF-LVAD的患者,从出院后首次门诊访视至装置使用12个月系统记录INR。
  • 采用多变量线性回归分析低TTR的危险因素,21个自变量进入逐步回归以最小化Akaike信息准则。

主要发现

  • 年龄每增加1岁与TTR增加0.4%相关(p=0.008)。
  • 距诊所每远1英里与TTR增加0.08%相关(p=0.03)。
  • 女性与TTR降低10.1%相关(p=0.04)。
  • 2型糖尿病与TTR降低11.5%相关(p=0.006)。
  • 既往华法林使用与TTR降低8.3%相关(p=0.03)。

临床怎么用

  • 对女性、合并2型糖尿病或有既往华法林使用史的CF-LVAD患者,可考虑加强INR监测和抗凝管理以改善TTR。

局限性

  • 回顾性单中心设计可能限制结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with a continuous-flow left ventricular assist device (CF-LVAD) require anticoagulation with a vitamin K antagonist to prevent thromboembolic events. Fluctuations in the international normalized ratio are associated with both increased thrombotic and bleeding episodes. To date, risk factors for low time in therapeutic range (TTR) among ambulatory patients with a CF-LVAD have not been explored. METHODS: A retrospective single-center analysis of 121 patients implanted with a CF-LVAD was performed. International normalized ratios were systematically recorded from the initial postdischarge outpatient visit to 12 months of time on the device. Risk factors for low TTR were evaluated using a multivariable linear regression analysis. Each of the 21 independent variables was entered into a stepwise regression designed to minimize the Akaike information criteria. RESULTS: In the multivariable analysis, the model output revealed that every 1-year increase in age was associated with a 0.4% increase in TTR (p=0.008), and every 1 mile further from clinic was associated with a 0.08% increase in TTR (p=0.03). Female sex was associated with a 10.1% decrease in TTR (p=0.04), type 2 diabetes was associated with an 11.5% decrease in TTR (p=0.006), and prior warfarin use was associated with an 8.3% decrease in TTR (p=0.03). CONCLUSION: In CF-LVAD recipients receiving warfarin, increasing age and distance from clinic are independent predictors of higher TTR. Female sex, type 2 diabetes, and prior warfarin use are independent predictors of lower TTR.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Henderson JB, Iyer P, Coniglio AC, et al. Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. Pharmacotherapy. 2019. PMID: 31463945. doi:10.1002/phar.2324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。